| __timestamp | Alkermes plc | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 205018000 |
| Thursday, January 1, 2015 | 483393000 | 392709000 |
| Friday, January 1, 2016 | 519270000 | 299694000 |
| Sunday, January 1, 2017 | 567637000 | 397061000 |
| Monday, January 1, 2018 | 601826000 | 434100000 |
| Tuesday, January 1, 2019 | 693218000 | 782200000 |
| Wednesday, January 1, 2020 | 572904000 | 1119900000 |
| Friday, January 1, 2021 | 603913000 | 2437500000 |
| Saturday, January 1, 2022 | 218108000 | 1560400000 |
| Sunday, January 1, 2023 | 253037000 | 1815800000 |
| Monday, January 1, 2024 | 245331000 | 1970500000 |
Igniting the spark of knowledge
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Alkermes plc have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Regeneron saw a staggering 785% increase, peaking in 2021, while Alkermes experienced a more modest 13% rise, with a notable dip in 2022. This divergence highlights Regeneron's aggressive growth strategy, reflected in its substantial R&D investments and product expansions. Meanwhile, Alkermes' steadier trajectory suggests a focus on sustainable operations. As the industry evolves, these trends offer valuable insights into the strategic priorities of leading biopharma companies. Investors and stakeholders should consider these patterns when evaluating future prospects and competitive positioning.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.
R&D Insights: How Regeneron Pharmaceuticals, Inc. and Alkermes plc Allocate Funds
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Perrigo Company plc's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down GSK plc and Alkermes plc's Expenses
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Alkermes plc
Analyzing Cost of Revenue: Alkermes plc and ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Alkermes plc and Vericel Corporation's Expenses
Comparing Cost of Revenue Efficiency: Alkermes plc vs Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Alkermes plc vs Taro Pharmaceutical Industries Ltd.